News | May 28, 2013

Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent

Xience Xpedition 48 has potential to reduce overall procedural costs

Xience Xpedition 48 Abbott Vascular CE mark Europe

May 28, 2013 — Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). Xience Xpedition 48 offers the same design and clinical outcomes of the Xience family of drug eluting stents in a 48 mm length. Abbott is the only major manufacturer to offer a coronary drug eluting stent greater than 38 mm in length. 

Studies indicate that physicians choose to use multiple shorter length stents to meet the challenges of treating long blockages — or lesions — in as many as 30 percent of interventional heart procedures, as conventional stent sizes may not always fully cover the lesion.[1] It has been shown, however, that the use of a single stent instead of multiple stents may result in several procedural benefits, including the use of fewer devices, less exposure to X-ray during the procedure and reduced procedure time, which could lead to economic benefits.[2]

"With global economic pressures impacting hospitals and health care systems around the world, products like Xience Xpedition 48 may provide important cost savings to the system," said Peter Smits, M.D., Maasstad Ziekenhuis, Rotterdam, the Netherlands. "I believe that this new treatment option, backed by the robust clinical outcomes of the Xience family of drug eluting stents, will help physicians in the treatment of long lesions."

Xience Xpedition 48 is supported by clinical evidence from the Xience family of drug-eluting stents, including data from more than 53,000 patients across more than 100 studies with long-term outcomes out to five years. 

Xience Xpedition is available in one of the broadest size matrices on the European market, with diameters ranging from 2.25-4 mm, including a 3.25 mm diameter, and now with lengths ranging from 8-48 mm.

In the United States, the Xience Xpedition and Xience Prime stent systems, including Xience Prime LL, are indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions ? 32 mm) with reference vessel diameters of ? 2.25 to ? 4.25 mm.

For more information: www.xiencestent.com

References:

1. Räber, L., Jüni, P. et al. "Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation." Journal of the American College of Cardiology 2010; 55(12):1178-88

2. Hoffman, R., Herrmann, G. et al. "Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings." The American Journal of Cardiology 2002; 90:460-464

3. Morgan, K.P., Kapur, A. & Beatt, K.J. "Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention." Heart 2004; 90:732-738.

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init